Last reviewed · How we verify

NCT00365027

Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.

Withdrawn NA Last updated 4 September 2015
What this trial tests

NA trial testing Delayed embryo transfer in Ovarian Hyperstimulation Syndrome. Withdrawn.

Quick facts

Lead sponsorHaEmek Medical Center, Israel
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment

Drugs / interventions tested

Conditions studied

Sponsor

HaEmek Medical Center, Israel

Who can join

18 and older, female only, with Ovarian Hyperstimulation Syndrome or Infertility Drugs. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It has been suggested that in IVF cycles where GNRH agonist is utilized for final oocyte maturation in patients at risk of ovarian hyperstimulation, pregnancy rates are reduced. We hypothesize that the use of GNRH antagonist reduces pregnancy rates through an effect on the endometrium and not oocyte quality, therefore better results may be obtained by not returning these embryos in a fresh cycle but rather cryopreserving them and returning them to the uterus and a later stage.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other HaEmek Medical Center, Israel trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00365027.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing